Skip to content
Dry Powder Inhalation Capsule (DPI) Allopathic

Catium Trio 150 mcg+50 mcg+80 mcg dry powder inhalation capsule (dpi)

Generic: Indacaterol + Glycopyrronium + Mometasone Furoate

Company: Incepta Pharmaceuticals Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength150 mcg+50 mcg+80 mcg
PackStrip: 330.00 taka

Reviewed by: not listed yet. Source: not listed yet.

Last updated January 12, 2026.

Compare

Same generic, same strength

Sorted by price per dry powder inhalation capsule (dpi). Ask your pharmacist before you switch brands.

Indacaterol + Glycopyrronium + Mometasone Furoate 150 mcg+50 mcg+80 mcg dry powder inhalation capsule (dpi)s

Prices as listed on BestinMeds.

1 brand listed
Catium Trio (this medicine)55.00 taka per dry powder inhalation capsule (dpi)

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Indacaterol + Glycopyrronium + Mometasone Furoate guide

Indications

  This is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta 2-agonist and a medium or high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous 12 months. This is not indicated for the relief of acute bronchospasm.

Dosage and administration

Patients should be made aware that inhalation capsules should be used regularly, even when asymptomatic. When treating patients with asthma, physicians should only prescribe inhalation capsules for patients not adequately controlled on a long-term asthma control medication containing a LABA and a medium or high dose inhaled corticosteroid and who experienced one or more asthma exacerbations in the previous year. As with other inhaled drugs containing beta 2-adrenergic agents, inhalation capsules should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. When beginning treatment with inhalation capsules patients who have been taking rapid onset, short duration, inhaled beta 2-agonists on a regular basis (e.g., q.i.d) should be instructed to discontinue the regular use of these drugs and use them only for symptomatic relief if they develop acute respiratory symptoms while taking inhalation capsules. It is crucial to inform patients that inhalation capsules should not be used to treat acute symptoms of asthma. Patients should be prescribed a rapid onset, short duration inhaled bronchodilator (e.g., salbutamol) to relieve acute symptoms such as shortness of breath and advised to have this available for use at all times. The recommended dose for patients 18 years of age and older: Inhalation of the content of 150/50/160 micrograms one capsule once daily in patients not adequately controlled with a combination of a long-acting beta 2-agonist and a medium or high dose of an inhaled corticosteroid. The maximum recommended dose is 150/50/160 micrograms once daily.

Side effects

This information is not available. Ask your doctor or pharmacist.

Precautions and warnings

This information is not available. Ask your doctor or pharmacist.

Pregnancy and lactation

Pregnant Women: There are insufficient data on the use of indacaterol, glycopyrronium and mometasone furoate in pregnant women to inform a drug-associated risk. Indacaterol and glycopyrronium were not teratogenic in rats and rabbits following subcutaneous or inhalation administration respectively. In animal reproduction studies with pregnant mice, rats and rabbits, mometasone furoate caused increased fetal malformations and decreased fetal survival and growth. This should only be used during pregnancy if the expected benefit to the patient justifies the potential risk to the fetus. Breast-feeding: There is no information available on the presence of indacaterol, glycopyrronium or mometasone in human milk, on the effects on a breastfed child, or on the effects on milk production. Other inhaled corticosteroids, similar to mometasone furoate, are transferred into human milk. Indacaterol, glycopyrronium and mometasone furoate have been detected in the milk of lactating rats. Glycopyrronium reached up to 10-fold higher concentrations in the milk of lactating rats than in the blood of the dam after intravenous administration.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250